Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 731 participants.

Also called NCT03021187

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 731 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03021187
  • EudraCT 2016-000988-16
Main results
  • Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial Diabetes care, 2019-12 DOI, PubMed 31530667, PMC7364672 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, France, Greece, India, Japan, Mexico, Poland, Puerto Rico, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03021187. Randomized; double masking; primary purpose treatment. Start 2017-02-02 (actual); primary completion 2018-01-18 (actual). Results posted on 2019-11-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
Acronym
PIONEER 8
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
semaglutide
Intervention (Drug)
semaglutide
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03021187
Content hash
0df47ca2450abdcef30f1b0cbec06c1aa24cd25066c8159422ac32456d78674d